Positive Results from QTORIN Study for Microcystic LM - MyChesCo
WAYNE, PA — Palvella Therapeutics, Inc. this week announced positive topline results from the Company’s Phase 2 study of QTORIN™ rapamycin in Microcystic Lymphatic Malformations (Microcystic LM). Microcystic LM is …
MyChesCo
